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ABSTRACT 
Background: Imaging such as Tc99m-HMPAO single photon emission computed tomography 
(SPECT), and positron emission tomography/ computed tomography (PET/CT) amyloid scans 
are used to aid the diagnosis of Alzheimer’s disease (AD). Objective: We aimed to correlate 
the ability of these modalities to differentiate Probable AD and Possible AD using the clinical 
diagnosis as a gold standard. We also investigated the correlation of severity of amyloid deposit 
in the brain with the diagnosis of AD. Methods: A retrospective study of 47 subjects (17 
Probable AD and 30 Possible AD) who were referred for PET/CT amyloid scans to our centre 
was conducted. Hypoperfusion in the temporo-parietal lobes on Tc99m-HMPAO SPECT and 
loss of grey-white matter contrast in cortical regions on PET/CT Amyloid scans indicating the 
presence of amyloid β deposit were qualitatively interpreted as positive for AD. SPECT and 
PET/CT were also read in combination (Combo reading). The severity of amyloid β deposit 
was semiquantitatively assessed in a visual binary method using a scale of Grade 0-4. The 
severity of amyloid β deposit was assessed in a visual binary method and a semi-quantitative 
method using a scale of Grade 0-4. Results: There was significant correlation of Tc99m-
HMPAO SPECT, PET/CT amyloid findings and Combo reading with AD. The sensitivity, 
specificity, PPV and NPV were 87.5%, 73.7%, 58.3% and 93.3% (SPECT); 62.5%, 77.4%, 
58.8% and 80.0% (PET/CT) and 87.5%, 84.2%, 70.0% and 30.0% (Combo reading) 
respectively. The grade of amyloid deposition was not significantly correlated with AD 
(Spearman’s correlation, p=0.687). Conclusion: There is an incremental benefit in utilizing 
PET/CT amyloid imaging in cases with atypical presentation and indeterminate findings on 
conventional imaging of Alzheimer’s disease. 
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